Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RMD 
ResMed Inc (RMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: RMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $293.47
1 Year Target Price $293.47
| 8 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.94% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 35.98B USD | Price to earnings Ratio 25.21 | 1Y Target Price 293.47 |
Price to earnings Ratio 25.21 | 1Y Target Price 293.47 | ||
Volume (30-day avg) 19 | Beta 0.87 | 52 Weeks Range 198.60 - 293.11 | Updated Date 12/10/2025 |
52 Weeks Range 198.60 - 293.11 | Updated Date 12/10/2025 | ||
Dividends yield (FY) 0.88% | Basic EPS (TTM) 9.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.35% | Operating Margin (TTM) 34.62% |
Management Effectiveness
Return on Assets (TTM) 14.19% | Return on Equity (TTM) 25.41% |
Valuation
Trailing PE 25.21 | Forward PE 22.94 | Enterprise Value 35959916151 | Price to Sales(TTM) 6.84 |
Enterprise Value 35959916151 | Price to Sales(TTM) 6.84 | ||
Enterprise Value to Revenue 6.84 | Enterprise Value to EBITDA 17.96 | Shares Outstanding 145966294 | Shares Floating 145048166 |
Shares Outstanding 145966294 | Shares Floating 145048166 | ||
Percent Insiders 0.62 | Percent Institutions 65.63 |
Upturn AI SWOT
ResMed Inc
Company Overview
History and Background
ResMed Inc. was founded in 1989 by Dr. Peter Farrell. Initially focused on developing advanced sleep apnea devices, the company has evolved into a global leader in cloud-connected medical devices for sleep, respiratory, and cardiovascular care. Key milestones include the development of its first CPAP device in the early 1990s, the introduction of its first PAP device with humidification in 1993, and its ongoing expansion into digital health solutions and remote patient monitoring.
Core Business Areas
- Sleep Apnea Devices: ResMed designs, manufactures, and markets devices for the diagnosis and treatment of sleep-disordered breathing (SDB), primarily Obstructive Sleep Apnea (OSA). This includes positive airway pressure (PAP) devices (CPAP, APAP, BiPAP), masks, and related accessories.
- Respiratory Care: This segment focuses on solutions for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It includes ventilators, non-invasive ventilation (NIV) devices, and humidifiers for both home and hospital use.
- Digital Health and Data Solutions: ResMed offers cloud-based platforms and software solutions that enable remote patient monitoring, data analytics, and improved patient management for healthcare providers. This is increasingly integrated across all its device offerings.
Leadership and Structure
ResMed is led by a dedicated executive team, with the Board of Directors overseeing strategic direction and corporate governance. The company operates on a global scale with distinct regional management structures to address local market needs. Key leadership roles typically include a CEO, CFO, and heads of various divisions such as Product Development, Sales & Marketing, and Operations.
Top Products and Market Share
Key Offerings
- AirSense 11 CPAP Machine: ResMed's latest generation CPAP machine, offering advanced features for sleep apnea treatment, including personalized therapy, integrated heated humidifier, and smartphone connectivity for app-based control and data access. Competitors include Philips Respironics (DreamStation series) and Fisher & Paykel Healthcare (Vitris series). Market share data for specific products is proprietary, but ResMed is a dominant player in the CPAP market.
- AirFit Series Masks: A range of comfortable and effective CPAP masks designed for various sleeping positions and facial structures. This includes full-face, nasal, and nasal pillow masks. Key competitors in the mask market include Philips Respironics, Fisher & Paykel Healthcare, and numerous smaller manufacturers. ResMed's AirFit line is highly regarded for its fit and comfort.
- Stellar Series Ventilators: Advanced ventilators for non-invasive and invasive ventilation for respiratory insufficiency, suitable for both home and hospital settings. Competitors include Philips Respironics (Trilogy series) and LTV series ventilators from other medical device companies.
- ResMed AirView: A cloud-based platform that allows clinicians to remotely monitor their patients' adherence and therapy data, adjust device settings, and troubleshoot issues. This is a key differentiator for ResMed and a significant component of its digital health strategy. Competitors include similar platforms from Philips and others offering remote monitoring solutions.
Market Dynamics
Industry Overview
The sleep and respiratory care industry is driven by an increasing prevalence of sleep disorders like Obstructive Sleep Apnea and chronic respiratory diseases such as COPD. Factors like aging populations, rising obesity rates, and increased awareness of sleep health contribute to market growth. The industry is also characterized by technological advancements in device design, digital connectivity, and remote patient monitoring.
Positioning
ResMed is a global leader in the sleep and respiratory care market, known for its innovation, product quality, and strong focus on digital health integration. The company benefits from a robust product portfolio, a strong brand reputation, and an established distribution network. Its commitment to cloud-connected devices and data analytics provides a competitive advantage in the increasingly digital healthcare landscape.
Total Addressable Market (TAM)
The global market for sleep apnea devices and related respiratory care is substantial and growing. Estimates vary, but the global sleep apnea market alone is projected to reach tens of billions of dollars in the coming years. ResMed is a significant player within this TAM, holding a substantial market share and actively expanding its reach through product innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand recognition and reputation for quality and innovation.
- Leading market share in key segments, particularly CPAP devices.
- Extensive global distribution network and established customer relationships.
- Significant investment in research and development, leading to advanced products.
- Pioneering role and strong capabilities in cloud-connected devices and digital health solutions.
- Diverse product portfolio addressing a broad range of sleep and respiratory conditions.
Weaknesses
- Reliance on a few key product categories for a significant portion of revenue.
- Potential for supply chain disruptions impacting manufacturing and distribution.
- Competition from both established medical device companies and emerging tech players.
- Regulatory hurdles and compliance requirements can impact product development timelines.
- Sensitivity to healthcare policy changes and reimbursement rates.
Opportunities
- Growing global awareness and diagnosis of sleep disorders.
- Increasing adoption of remote patient monitoring and telehealth solutions.
- Expansion into emerging markets with rising healthcare expenditure.
- Development of new therapeutic areas and connected care solutions.
- Strategic acquisitions to broaden product offerings or market reach.
- Leveraging AI and machine learning for enhanced diagnostic and therapeutic insights.
Threats
- Intense competition from major players like Philips Respironics and newer entrants.
- Potential for regulatory changes impacting device approval and market access.
- Reimbursement challenges and pricing pressures from payors.
- Economic downturns affecting healthcare spending.
- Cybersecurity threats to connected medical devices and patient data.
- Product recalls or safety concerns could damage brand reputation.
Competitors and Market Share
Key Competitors
- Philips (PHG)
- Fisher & Paykel Healthcare (FPH.NZ)
- 3B Medical Inc.
Competitive Landscape
ResMed possesses a strong competitive advantage due to its advanced technology, particularly in cloud connectivity and data analytics, as well as its reputation for quality and patient comfort. However, it faces significant competition from established players like Philips, which also offers a broad range of respiratory devices and has a strong global presence. Fisher & Paykel Healthcare is a strong competitor in humidification and respiratory consumables. Emerging players like 3B Medical are also gaining traction with innovative and cost-effective solutions.
Major Acquisitions
Propeller Health
- Year: 2022
- Acquisition Price (USD millions): 236
- Strategic Rationale: Propeller Health develops a digital health platform and smart inhaler sensors that track medication use for respiratory conditions like asthma and COPD. This acquisition strengthens ResMed's digital health capabilities and expands its offering in the broader respiratory care market.
Medi-Lease
- Year: 2022
- Acquisition Price (USD millions): 118
- Strategic Rationale: Medi-Lease is a leading provider of CPAP therapy services and equipment in Australia. This acquisition aims to enhance ResMed's direct-to-patient service offerings and expand its footprint in the Australian market.
Growth Trajectory and Initiatives
Historical Growth: ResMed has experienced consistent historical growth, driven by the increasing prevalence of sleep disorders, its leadership in innovative product development, and the expansion of its digital health offerings. The company has successfully transitioned from a hardware-focused business to a more integrated connected care provider.
Future Projections: Analyst consensus for ResMed's future growth remains positive, with expectations of continued revenue expansion driven by market penetration, new product launches, and the increasing adoption of its digital health solutions. Projections often anticipate mid-to-high single-digit or low double-digit annual revenue growth.
Recent Initiatives: Recent strategic initiatives by ResMed include the continued rollout and enhancement of its cloud-connected device ecosystem, focusing on remote patient monitoring and data analytics for improved clinical outcomes and operational efficiency. The company also actively pursues strategic acquisitions to complement its existing portfolio and expand into new therapeutic areas or geographies.
Summary
ResMed Inc. is a robust and well-positioned company in the growing sleep and respiratory care market. Its strengths lie in its innovative, cloud-connected devices, strong brand, and established distribution. The company is effectively leveraging digital health and remote monitoring to enhance patient care and clinician efficiency. While facing stiff competition, its strategic focus on technology and patient outcomes provides a solid foundation for continued growth and market leadership.
Similar Stocks
Sources and Disclaimers
Data Sources:
- ResMed Inc. Investor Relations website
- SEC Filings (10-K, 10-Q)
- Financial news and analysis platforms (e.g., Bloomberg, Reuters, Yahoo Finance)
- Market research reports on the sleep and respiratory care industry
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data presented is based on publicly available information and market estimates, and may not be exhaustive or perfectly current. Users are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is an estimation based on available industry reports and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.resmed.co.in |
Full time employees 10600 | Website https://www.resmed.co.in | ||
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.